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The immunotherapy candidate
TNFSF4 may help the induction
of a promising immunological
response in breast carcinomas
Kai Li1,2,7, Lei Ma3,7, Ye Sun4,7, Xiang Li1,2,5, Hong Ren1,2, Shou‑Ching Tang6* & Xin Sun1,2*
Immune checkpoint blockade, an immunotherapy, has been applied in multiple systemic
malignancies and has improved overall survival to a relatively great extent; whether it can be applied
in breast cancer remains unknown. We endeavored to explore possible factors that may influence
immunotherapy outcomes in breast cancer using several public databases. The possible treatment
target TNF superfamily member 4 (TNFSF4) was selected from many candidates based on its abnormal
expression profile, survival-associated status, and ability to predict immune system reactions. For the
first time, we identified the oncogenic features of TNFSF4 in breast carcinoma. TNFSF4 was revealed
to be closely related to treatment that induced antitumor immunity and to interact with multiple
immune effector molecules and T cell signatures, which was independent of endocrine status and
has not been reported previously. Moreover, the potential immunotherapeutic approach of TNFSF4
blockade showed underlying effects on stem cell expansion, which more strongly and specifically
demonstrated the potential effects of applying TNFSF4 blockade-based immunotherapies in breast
carcinomas. We identified potential targets that may contribute to breast cancer therapies through
clinical analysis and real-world review and provided one potential but crucial tool for treating breast
carcinoma that showed effects across subtypes and long-term effectiveness.
Abbreviations
TNFRSF14	TNF receptor superfamily member 14
TNFSF4	TNF superfamily member 4
TNFSF18	TNF superfamily member 18
CD274	PD-L1
DCD1LG2	PD-L2
Breast carcinoma treatments have been evolving for years, accompanied by the emergence of reagents referred to
as endocrine therapy and targeted therapy and improvements in chemotherapeutics1,2. However, the development
of therapies seems to have encountered a bottleneck, and what approach should be pursued to further prolong
patient survival is unclear3–5. Can we draw lessons from the experience of immunotherapy?
Improving cancer-related immune resistance is mainly achieved through immune checkpoint blockade therapy, and multiple immune checkpoint-targeting agents have been identified and clinically applied to treat lung
cancer, esophageal cancer, melanoma, etc. Therapeutic targets include but are not limited to PD-L1 (CD274),
PD-L2 (PDCD1LG2), CD80, CD86, and CD70, and novel applied therapies have shown promise in lung cancer
and melanoma treatment6–10. However, how immune checkpoint blockade therapy acts in the breast cancer
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treatment process and what checkpoint may be targeted to achieve benefits are totally unknown. Recently, CCR9
was demonstrated to exert strong immunoregulatory effects on T cell responses in multiple tumors, and through
inhibiting TCR signaling, CCR9 regulates STAT signaling in T cells, resulting in reduced T helper 1 cytokine
secretion. Unlike PD-L1 blockade, inhibition of CCR9 expression on tumor cells facilitates immunotherapeutic
effects via tumor-specific T cells in vivo11,12. However, whether and how such immune checkpoints are involved
in breast cancer prognosis and therapeutic efficacy remain largely unclear.
Therefore, this study aimed to clarify the clinical significance of immunotherapies, especially the uncertain
efficacy of immune checkpoint blockade, in breast cancer patients and to propose more suitable strategies for
improving breast cancer treatments by applying our knowledge on immunity.

Results

Screening possible immune functions related to anticancer treatment.

Common immune
checkpoints were browsed and screened for possible immunotherapeutic value, and the representative immune
checkpoint molecules13–15 ADORA2A, BTLA, Nectin-2 (CD112), CD160, CD244, PD-L1, CD96, CSF1R,
CTLA4, HAVCR2, IDO1, IL10, IL10RB, KDR, KIR2DL1, KIR2DL3, LAG3, LGALS9, PDCD1, PDCD1LG2,
PVRL2, TGFB1, TGFBR1, TIGIT, VTCN1, TNF Receptor Superfamily Member 14 (TNFRSF14), TNF superfamily member 4 (TNFSF4), and TNF superfamily member 18 (TNFSF18) were all input into the Tumor and
Immune System Interaction Database (TISIDB) for potential effect predication in the integrated repository portal for tumor-immune system interactions16. Primarily, PD-L1, CD112, TNFRSF14, TNFSF4, TNFSF18, CD48,
and LGALS9 were selected for their significant differential expression patterns, and the patterns are shown in
Fig. S1. The paired red and green colors indicate the expression patterns in multiple organs and systems.
Furthermore, PD-L1 (Fig. 1A), CD112 (Fig. 1B), TNFRSF14 (Fig. 1C), TNFSF4 (Fig. 1D), TNFSF18 (Fig. 1E),
CD48 (Fig. 1F), and LGALS9 (Fig. 1G) were analyzed for abnormal expression patterns in breast carcinomas.
Specifically, CD112, TNFSF4, TNFSF18, and LGALS9 were significantly overexpressed in breast carcinomas,
strongly suggesting potent and valuable effects.

Immunotherapeutic targets participated in multiple breast carcinogenic processes by inter‑
acting with key cancer‑stimulating factors. The heterogenetic features of breast cancer cause breast

carcinomas with different hormone receptor statuses to benefit from different and specific treatment strategies.
As a double-edged sword, a specific agent will not function in another kind of breast carcinoma, and to determine the potential of immune checkpoint blockade therapies, native expression signatures and correlations were
studied using cBioPortal and Gene Expression Profiling Interactive Analysis 2 (GEPIA2). An expression heatmap was used to visualize the expression patterns of the candidates in red bars, and the selected representative
genes described in the first part of Result section are labeled with a red star (Fig. 2A). The analysis flowchart is
shown in Fig. 2B. All the enrolled factors were input and studied for potential functional correlations (Fig. S2).
Specifically, the main oncogenes ERBB2, KRAS, and TP53 were analyzed for their intrinsic connections in
breast carcinomas, and promising correlations between TNFSF4 and ERBB2, KRAS, and TP53 were confirmed
(Fig. S3, Table 1).
In general, nearly all the immunotherapeutic targets showed expanded expression intervals in ESR1+ and
PGR+ cases, the existence of which demonstrated a better response to standard (“chemotherapeutic”) and antihormone treatments, indicating that immunotherapy may compensate for current deficiencies. More importantly
and interestingly, TNFSF4, TNFSF18, and CD48 all showed increased expression in breast carcinomas bearing
no ERBB2, ESR1, or PGR expression, strongly suggesting that immunotherapy may show efficacy in all types
of breast cancer, and a partially enlarged drawing is shown in Fig. 2C. In detail, TNFSF4, TNFSF18 and CD48
showed aberrant expression in breast cancer cases with different genetic backgrounds, including those without
KRAS (Fig. 2D), TP53 (Fig. 2E), or ERBB2 (Fig. 2F) expression and activation; these three factors dominated
the survival prognosis and led to short predicted survival.

Evaluation of the cluster of TNFSF4, TNFSF18, CD48 and LGALS9 as therapeutic immune
therapeutic targets. The clinical significance of a cluster including TNFSF18 (Fig. 3A), LGALS9 (Fig. 3B),

TNFSF4 (Fig. 3C) and CD48 (Fig. 3D) was also analyzed for the value of these molecules as immunotherapeutic
targets, and TNFSF4 and TNFSF18 showed greater significance in predicting disease-free survival and overall
survival (OS). KRAS greatly stimulated carcinogenesis and determined the anticancer treatment response. We
further explored the correlations of KRAS with TNFSF18 (Fig. 3E), LGALS9 (Fig. 3F), TNFSF4 (Fig. 3G) and
CD48 (Fig. 3H), and the positive correlation between TNFSF4 and KRAS strongly suggested the prospect of
achieving therapeutic effects by using TNFSF4 as a target for manipulation or blockade.
Groups of stem cells are considered the root of cancer recurrence due to their steady status and superior
renewal ability. We previously identified stem-like ALDH1A1+ cells in breast cancer g roups2,17,18, and in this
study, we noticed a close correlation between TNFSF4 and ALDH1A1 expression (Fig. 3I), the latter of which
indicated shorter survival (Fig. 3J) and progression-free times (Fig. 3K). These results strongly suggested that
oncogenic TNFSF4 may be an effective immunotherapeutic target, and the proposed survival benefits may also
be achieved by repressing stem cell expansion, fully assuring a positive outcome for anti-TNFSF4 treatment.
The other candidates, CD112, TNFRSF14, and PD-L1, failed to be involved upon further analysis, as indicated
by their negative associations with survival (Fig. S4).

Probable mechanism by which TNFSF4 functions. The immune system becomes suppressed as car-

cinomas become aggressive, and when immune function inhibitors are applied (immune blockade approaches),
active immune cells begin to infiltrate and execute cellular functions (Fig. 4A). All types of cancer cells, includ-
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Figure 1.  Analyzing candidate immune checkpoint molecules targeted by blockade in carcinomas. Carcinomas
throughout the body were enrolled for analysis, and multiple systems showed various immune checkpoint
molecule patterns. PD-L1 (A), CD112 (B), TNFRSF14 (C), TNFSF4 (D), TNFSF18 (E), CD48 (F), and LGALS9
(G) were analyzed for abnormal expression in breast carcinomas. In each image, the specific quantitative value
is shown at the top, and each dot represents the expression in samples. The bar graphs below were used for
comparison, and bar height bar represents the median expression of the specific tumor type or normal tissue.
Specifically, CD112, TNFSF4, TNFSF18, and LGALS9 were relatively overexpressed in breast carcinomas.
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Figure 2.  Selection of the most representative immune checkpoint molecules targeted by blockade. Expression
signatures and correlations were studied using cBioPortal and GEPIA2. (A) Expression heat-map showing
the expression of each candidate in a red bar, and the most representative genes are labeled with a red star.
The red bars indicate actual data points, and the gray bars indicate that no specific data were available. (B)
The analysis flowchart is shown. (C) Nearly all the immunotherapeutic targets showed expanded expression
intervals referring to ESR1 and PGR, and TNFSF4, TNFSF18, and CD48 showed increased expression in breast
carcinomas without ERBB2, ESR1, and PGR expression. Amplification or mutation of KRAS (D), TP53 (E), or
ERBB2 (F) indicated worse predicted survival.
ing the heterogenetic subtype cells known as cancer stem cells (CSCs), can be eliminated by immune attack.
To investigate the crucial role of the selected immune target, infiltrating lymphocyte functions and connective
functional factors were analyzed for insights into the underlying mechanisms. Both ALDH1A1 overexpression
(Fig. 4B) and TNFSF4 (Fig. 4C) overexpression correlated with more active lymphocytes. However, infiltrating immune cells were suppressed by highly expressed immune inhibitors on cells with increased ALDH1A1
(Fig. 4D) or TNFSF4 expression (Fig. 4E). These results indicated that TNFSF4 can potentially reactivate the
immune response and partially function by precisely neutralizing stem cells.

Stem cell signatures predicted the response to immunotherapy.

Immunotherapy responses and
effects were believed to be correlated with lymphocyte activation and infiltration, and we first assessed the effects
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Table 1.  The analysis tested in 276 pairs between the 24 tracks in the OncoPrint to reveal the connections
among immunotherapies related genes. The close connections among the candidate immune checkpoints, and
the connections among checkpoints and malignancy stimulators of either KRAS, TP53, ERBB2, ALDH1A1,
CD44, were all calculated and exhibited. The close connections strongly suggested the crucial roles of candidate
immune checkpoints in therapy response, and also suggested the potential effects they may exert.

of immunotherapies in multiple systems. Treatments targeting TNFSF4 tended to produce relatively good outcomes (Fig. 5A). Additionally, TNFSF4-associated TP53 (Fig. 5B), KRAS (Fig. 5C), and ERBB2 (Fig. 5D) all
indicated a relatively good immunotherapy response, which further supported the crucial position of TNFSF4.
Red-labeled text refers to one specific study, and detailed study information can be reviewed by searching certain
PMID numbers in TISIDB.
TNFSF4 and ALDH1A1 were confirmed to participate in immune-activating therapies, and TNFSF4 treatment predicted a therapeutic response. Immunotherapy consistently repressed tumor growth once the immune
system was activated, and from the above results, we further found that TNFSF4-associated therapy might
also influence stem cell expansion. Increased ALDH1A1 expression indicated shorter disease-specific survival
(Fig. 5E) and overall survival (Fig. 5F), and in clinical assessments, ALDH1A1 surprisingly correlated with higher
therapeutic response ratios (Fig. 5G), which has not ever been reported or analyzed.
Associations between ALDH1A1 expression and immune subtypes across human cancers were included for
analysis, and ALDH1A1 expression dominated in all the subtypes (Fig. 5H), participating in multiple immune
reaction processes (Fig. 5I). Associations between ALDH1A1 expression and molecular subtypes across human
cancers were also identified (Fig. 5J), and a signature of increasing ALDH1A1 levels tended to be observed in all
kinds of breast carcinoma (Fig. 5K), indicating the universal therapy-responsive role of ALDH1A1 in achieving
better outcomes.

Preliminary exploration of clinical significance. Immunohistochemical (IHC) staining images were

acquired from “The Human Protein Atlas” project (funded by the Knut & Alice Wallenberg Foundation), and
representative images were arranged referring to different groups in the public dataset (Fig. 6A). High expression of TNFSF4 was universally identified in breast carcinoma (Fig. 6B) and pointed to poorer survival outcomes
(Fig. 6C,D). To further verify the potential effects of TNFSF4 on stem cell renewal, we isolated stem cells and
identified higher TNFSF4 expression in the CD44+/24− cell group with the luminal A/B phenotype (Fig. 6E) and
in the ALDH1A1+ cell group with the basal-like phenotype (Fig. 6F). For the first time, we derived solid results
through database screening and bench-to-clinic exploration; the results strongly suggested the value of TNFSF4based immunotherapy (Fig. 6G,H).
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Figure 3.  Clinical evaluations of potential therapeutic candidates. Data were acquired from the combined study
cohorts of BREAST (METABRIC 2016), BREAST CANCER (MSK 2018), and BREAST INVASIVE CARCINOMA
BREAST (TCGA PANCAN 2018). The clinical significance of the cluster including TNFSF18 (A), LGALS9 (B),
TNFSF4 (C) and CD48 (D) was analyzed for the value of these molecules as immunotherapeutic targets. The
correlations between KRAS and TNFSF18 (E), LGALS9 (F), TNFSF4 (G) or CD48 (H) were analyzed, and the
positive correlation between TNFSF4 and KRAS strongly suggested the prospective therapeutic effects of using
TNFSF4 as target for manipulation or blockade. (I) A close correlation between TNFSF4 and ALDH1A1 expression
was identified. Stem cells with a positive ALDH1A1 phenotype had a shorter survival time (J) and shorter
progression-free time (K).
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Figure 4.  TNFSF4-based immunotherapy may intersect with cancer stem cell signature repression. (A)
Schematic figure illustrating the immune response. the immune system becomes suppressed when a carcinoma
becomes aggressive. Later, when immune function inhibitors are blocked, active immune cells begin to
infiltrate and exert cytotoxic activities against all tumor cells. Spearman correlations between TNFSF4 and
immunoinhibitory factors (Y axis) across human cancers (X axis). The items in the column are listed in
sequence as follows: ADORA2A, BTLA, CD160, CD244, CD274, CD96, CSF1R, CTLA4, HAVCR2, IDO1,
IL10, IL10RB, KDR, KIR2DL1, KIR2DL3, LAG3, LGALS9, PDCD1, PDCD1LG2, PVRL2, TGFB1, TGFBR1,
TIGIT, and VTCN1. The infiltrating lymphocyte functions and connective functional factors were analyzed, and
both ALDH1A1 overexpression (B) and TNFSF4 overexpression (C) were correlated with more lymphocyte
infiltration. Spearman correlations between TNFSF4 and kinds of lymphocytes (Y axis) across human cancers
(X axis). The items in the column are listed in sequence as follows: ADORA2A, BTLA, CD160, CD244,
CD274, CD96, CSF1R, CTLA4, HAVCR2, IDO1, IL10, IL10RB, KDR, KIR2DL1, KIR2DL3, LAG3, LGALS9,
PDCD1, PDCD1LG2, PVRL2, TGFB1, TGFBR1, TIGIT, and VTCN1. However, infiltrating immune cells were
suppressed by highly expressed immune inhibitors in cells with increased ALDH1A1 (D) or TNFSF4 expression
(E). These results indicated that TNFSF4 blockade treatment could potentially reactivate the immune response
and partially function through precisely inhibiting stem cells.
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Figure 5.  TNFSF4 blockade therapies could be assessed in the stem cell signature-associated mode. The
transcriptomic and genomic profiles of pretreated tumor biopsies from responders and non-responders treated
with anti-PDL1 and anti-PD1 antibodies were enrolled for analysis. In total, the responders tended to exhibit
higher TNFSF4 expression levels, and each study could be reviewed by searching for a certain PMID number
(red labeling). Assessment of real-world immunotherapeutic effects indicated that effects related to TNFSF4 (A)
tended to imply better outcomes and that TNFSF4-associated TP53 (B), KRAS (C), and ERBB2 (D) all indicated
better immunotherapy response. Increased ALDH1A1 expression indicated shorter disease-specific survival
(E) and overall survival (F), and ALDH1A1 surprisingly correlated with higher therapeutic response ratios
(G) through clinical data assessment. (H,I) ALDH1A1 was analyzed for its roles in predicting immunotherapy
response, and the 5 subgroups C1 (N = 369), C2 (N = 390), C3 (N = 191), C4 (N = 92), and C6 (N = 40) were
involved in assessing functional aspects. ALDH1A1 expression dominated in all the subtypes, participating in
multiple immune reaction processes. (J,K) Associations between ALDH1A1 expression and molecular subtypes
across human cancers were also identified, and the signature of increasing ALDH1A1 expression tended to be
found in all kinds of breast carcinomas. Specifically, C1 represents wound healing, C2 represents IFN-gamma
dominant, C3 represents inflammatory, C4 represents lymphocyte depleted, C5 represents immunologically
quiescent and is not shown, and C6 represents TGF-b dominant.
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Figure 6.  Exploration of the putative clinical roles of TNFSF4. (A) IHC staining images are shown to clarify
different expression patterns (left to right, in sequence, < 25%, 25–75%, and > 75%). A lymph node slide was set
as a positive control, and an unstained slide was set as a negative control. (B) High RNA expression of TNFSF4
was universally identified in breast carcinoma, with testing and calculation based on FPKM, and the cutoff line
is labeled, which was used for clinical predictions. (C,D) Higher TNFSF4 expression pointed to poorer survival
outcomes. (E,F) Flow cytometry with FACSAria sorting was applied to isolate stem cells from ZR75-1, MCF-7,
and MM-231 cells. (G,H) Stem cells with a CD44+/24− or ALDH1A1+ phenotype were identified and isolated,
and the TNFSF4 expression patterns in different cell lines were checked to illustrate the increased expression.
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Discussion

The treatment approaches for breast carcinoma are constantly evolving in accordance with newly confirmed
molecular and biological findings, which lead to reconfiguration of treatment methods. Shifting treatment strategies may expand benefits across various carcinomas; however, immunotherapy is not yet effective in most
malignancies. Several specific contributions have been identified for breast carcinogenesis, and related therapies
that target or relieve the malignant process have greatly improved patient lives. Currently, endocrine therapy,
anti-Her-2 therapy, and improved chemotherapy all prolong survival outcomes. We must confront the fact that
basal-like breast carcinoma, which is always identified as triple-negative carcinoma, is without any endocrine
factors or precise targets for treatment. As an example, immunotherapy has been used across the squamous,
adenocarcinoma, and small cell types of lung cancer, indicating universal inhibition. To explore potential effective
immune targets, we first input all immunotherapy-related functional factors, and after screening in all kinds of
breast carcinomas, several candidates were selected, and their correlations with aggressive breast carcinogens
were analyzed to evaluate the possible effects of targeted therapy. To finally identify the most promising immunotherapy candidate, the selected factors were assessed for clinical significance (Fig. 2B).
TNFSF4 belongs to the tumor necrosis factor ligand family and functions in T cell-antigen-presenting cell
(APC) interactions, mediating the adhesion of activated T cells to target cells. TNFSF4 can bind to TNFRSF4 and
collaboratively stimulate T cell proliferation and cytokine production. There are only limited studies exploring
the possible functions of TNFSF419,20, and the roles of TNFSF4 in breast carcinoma are unknown. We found
that TNFSF4 was highly expressed in all kinds of breast carcinomas, and its aberrant overexpression was associated with shorter overall survival and disease-free survival. Importantly, TNFSF4 was further revealed to be
closely related to antitumor immunity, including multiple immune effector molecules and T cell signatures, as
presented and illustrated.
In conclusion, TNFSF4 is a potential immunotherapy target due to its aberrant expression pattern in breast
carcinoma, and this protein was even found to be overexpressed in carcinomas without ERBB2, ESR1, or PGR1
amplification and those without either KRAS or TP53 mutation and amplification. TNFSF4, together with other
candidates, was included for evaluation, and the positive correlations with immune function inhibitors and
lymphocytes drew much attention. In the clinical case analysis, TNFSF4-targeted therapy might show the best
response to therapy, and interestingly, TNFSF4 also perturbed stem cell expansion, a signature that is critical for
long-term recurrence and response to therapy. Therefore, for the first time, we aimed to identify the key factors
that may contribute to breast cancer therapies and provide one potential but crucial approach for treating all
types of breast carcinoma with long-term effectiveness.

Methods and materials

Database availability and integrated analysis. To analyze immune checkpoint-related prognoses

in breast cancer, breast cancer genomics-related datasets in The Cancer Genome Atlas (TCGA, http://cance
rgenome.nih.gov) and International Cancer Genome Consortium (ICGC, https://icgc.org) were individually
collected and subsequently subjected to bioinformatic analysis with the web servers GEPIA2 (http://gepia2.cancer-pku.cn)21,22, cBioPortal for Cancer Genomics (http://www.cbioportal.org)23,24, and TISIDB (http://cis.hku.
hk/TISIDB)25,26. In detail, GEPIA2 was used to calculate prognostic indexes, including differential expression,
pathological stage, gene correlations, and patient survival; cBioPortal was used to visualize and compare gene
alterations; and TISIDB was used to explore correlations between the abundances of immunomodulators and
the expression of the investigated genes.
Tumor-infiltrating lymphocytes were analyzed using TISIDB27 and the immune-related signatures of 28
tumor-infiltrating lymphocyte types from Charoentong’s study (https://w
 ww.c ell.c om/c ell-r eport s/f ullte xt/S 2211-
1247(16)31709-0), which can be viewed on the download page. The relative abundances of tumor-infiltrating
lymphocytes were inferred by using gene set variation analysis (GSVA) based on the gene expression profile.
Overall survival and disease-free survival analyses were performed using the Kaplan–Meier method with a 50%
cutoff to separate the low- and high-expression groups. The log-rank test, also known as the Mantel–Cox test,
was used for the hypothesis test. The Cox proportional hazard ratio (HR) and 95% confidence interval were also
included in survival plots. A P value < 0.05 was considered statistically significant.

Clinical data analysis. The cutoff (FPKM) was set based on the FPKM value of each gene. When applying

survival curve analysis, patients were classified into two groups, and the association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cutoff referred to the FPKM value that
yielded the maximal difference with regard to survival between two groups at the lowest log-rank P value. The
best expression cutoff was selected based on survival analysis. Median expression referred to the median FPKM
value calculated based on the gene expression (FPKM) data from all patients in the dataset. The median followup time referred to the median time (years) after diagnosis with a specific type of cancer based on clinical data
from a public dataset.

Stem cell isolation and RNA quantification. The breast cancer cell lines MCF-7, ZR75-1, and MM-231

were purchased from American Type Culture Collection and maintained in DMEM (Gibco) or RPMI 1640
medium (HyClone). Total mRNA was reverse transcribed into cDNA by using an RT-PCR kit (AT301 TransGen
Biotech), and real-time quantitative PCR (RT-qPCR) was performed with a CFX96 Real-Time PCR Detection
System (Bio-Rad)17,18. For analysis of the expression of the breast cancer stem cell (BCSC) markers CD44 and
CD24, cells in different treatment groups were collected and washed with PBS twice. Then, the cells were incubated with anti-CD44-FITC (clone G44-26) and anti-CD24-PE (clone ML5) antibodies (Invitrogen) at 4 °C for
30 min. After two washes, the samples were analyzed using a flow cytometer (FACSCalibur, BD Biosciences)28,29.
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An LSRII flow cytometer (BD Biosciences Pharmingen, San Diego, USA) was used to analyze and separate
CSCs based on cell labeling and fluorescence-activated cell sorting. The activated ALDEFLUOR reagent and
DEAM purchased from STEMCELL Technologies (Vancouver, BC, Canada) were used to isolate aldehyde
dehydrogenase (ALDH+) cells (stem-like cells). The percentages of ALDH1+ stem cells in different groups were
analyzed5,18.

Statistical significance and classification. The Spearman method was used to analyze pairwise gene

expression correlations, and a P value < 0.05 was considered statistically significant. The correlation degree
was identified from the absolute value of the correlation coefficient, and the detailed classifications were as
follows: ≤ 0.4, weak; 0.41–0.60, moderate; 0.61–0.80, strong; and 0.81–1.0, very strong. The cooccurrence and
mutual exclusivity of genetic alterations between genes of interest and each immune checkpoint molecule were
determined from the log2 odds ratio, P value, and Q value. A Q value < 0.05 was considered statistically significant. The investigated immune inhibitors were collected according to Charoentong’s study27,30,31, and each Spearman correlation between the investigated genes and a distinct immune inhibitor in an individual cancer type
was integrated into the indicated heat-map. Log-rank P values for Kaplan–Meier plots represents results from an
analysis of the correlation between an mRNA expression level and patient survival.

Ethics approval and consent to participate. All procedures performed in the studies involving human
participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards for retrospective studies. We confirmed that the IHC results of the human participants were generated in “The Human
Protein Atlas” project (www.proteinatlas.org), and the representative images were arranged referring to different
groups in the public dataset.
Consent for publication. The authors declare that each author has approved this article for publication.

Data availability

The data and relevant supporting materials related to the findings of this study are available from the corresponding author upon reasonable request.
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